Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1463-1470

  Ballestrero, Alberto ^a,c   Nencioni, Alessio ^a,b   Boy, Davide ^a   Rocco, Ilaria ^a   Garuti, Anna ^a   Mela, Giuseppe Sandro ^a   Van Parijs, Luk ^b   Brossart, Peter ^b   Wesselborg, Sebastian ^b   Patrone, Franco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; OXALIPLATIN; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; DOSE RESPONSE; DRUG POTENTIATION; DRUG RESISTANCE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; RADIOSENSITIVITY;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CASPASE 3; CASPASE 8; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; ETOPOSIDE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; LIGANDS; LYMPHOMA; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12144289654     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1365-02     Document Type: Article

References (57)

1. Ngan, B-Y., Chen-Levy, Z., Weiss, L. M., Warnke, R. A., and Cleary, M. L. Expression in non-Hodgkin's lymphoma of the BCL-2 protein associated with the t(14;18) chromosomal translocation. N. Eng. J. Med., 318: 1638-1644, 1988.
2. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334-336, 1990.
3. Hengartner, M. O. The biochemistry of apoptosis. Nature (Lond.), 407: 770-776, 2000.
4. Adams, J. M., and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science (Wash. DC), 281: 1322-1326, 1998.
5. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Wash. DC), 275: 1132-1136, 1997.
6. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P., and Wang, X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (Wash. DC), 275: 1129-1132, 1997.
7. L regulates the membrane potential and volume homeostasis of mitochondria. Cell 91: 627-637, 1997.
8. Los, M., Wesselborg, S., and Schulze-Osthoff, K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity, 10: 629-639, 1999.
9. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell. Biochem., 60: 23-32, 1996.
10. Evan, G. I., and Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature (Lond.), 411: 342-348, 2001.
11. Yunis, J. J., Mayer, M. G., Arnesen, M. A., Aeppli, D. P., Oken, M. M., and Frizzera, G. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Eng. J. Med., 320: 1047-1054, 1989.
12. Hill, M. E., MacLennan, K. A., Cunningham, D. C., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., Selby, P., and Linch, D. C. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood, 88: 1046-1051, 1996.
13. Kramer, M. H., Hermans, J., Parker, J., Krol, A. D., Kluin-Nelemans, J. C., Haak, H. L., van Groningen, K., van Krieken, J. H., de Jong, D., and Kluin, P. M. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J. Clin. Oncol., 14: 2131-2138, 1996.
14. Barrans, S. L., Carter, I., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A. P., Morgan, G. J., and Jack, A. S. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 99: 1136-1143, 2002.
15. Krammer, P. H. CD95's deathly mission in the immune system. Nature (Lond.), 407: 789-795, 2000.
16. Schulze-Osthoff, K., Ferrari, D., Los, M., Wesselborg, S., and Peter, M. E. Apoptosis signaling by death receptors. Eur. J. Biochem., 254: 439-459, 1998.
17. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
18. Li, H., Zhu, H., Xu, C. J., and Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94: 491-501, 1998.
19. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94: 481-490, 1998.
20. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature (Lond.), 407: 810-816, 2000.
21. Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., and Smyth, M. J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol., 168: 1356-1361, 2002.
22. Jo, M., Kim, T. H., Seol, D. W., Esplen, J. E., Dorko, K., Billiar, T. R., and Strom, S. C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med., 6: 564-567, 2000.
23. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C., and Lynch, D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5: 157-163, 1999.
24. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Investig., 104: 155-162, 1999.
25. Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., and Rehemtulla, A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA, 97: 1754-1759, 2000.
26. Wesselborg, S., Engels, I. H., Rossmann, E., Los, M., and Schulze-Osthoff, K. Anticancer drugs induce caspase-8/FLICE activation in the absence of CD95 receptor/ligand interaction. Blood, 9: 3053-3063, 1999.
27. Engels, I. H., Stepczynska, A., Stroh, C., Lauber, K., Berg, C., Schwenzer, R., Wajant, H., Janicke, R. U., Porter, A. G., Belka, C., Gregor, M., Schulze-Osthoff, K., and Wesselborg, S. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene, 19: 4563-4573, 2000.
28. Lauber, K., Appel, H. A. E., Schlosser, S. F., Gregor, M., Schulze-Osthoff, K., and Wesselborg, S. The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. J. Biol. Chem., 276: 29772-29781, 2001.
29. Castedo, M., Ferri, K., Roumier, T., Metivier, D., Zamzami, N., and Kroemer, G. Quantitation of mitochondrial alterations associated with apoptosis. J. Immunol. Methods, 265: 39-47, 2002.
30. Layer, K., Lin, G., Nencioni, A., Hu, W., Schmucker, A., Antov, A. N., Li, X., Takamatsu, S., Chevassut, T., Dower, N. A., Stang, S. L., Beier, D., Buhlmann, J., Bronson, R. T., Elkon, K. B., Stone, J. C., Van Parijs, L., and Lim, B. Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity, 19: 243-255, 2003.
31. Fischel, J-L., Rostagno, P., Formento, P., Dubreuil, A., Etienne, M-C., and Milano, G. Ternary combination of irinotecan, fluorouracilfolinic acid and oxaliplatin: results on human colon cancer cell lines. Br. J. Cancer, 84: 579-585, 2001.
32. Desoize, B., and Madoulet, C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol., 42: 317-325, 2002.
33. Woynarowski, J. M., Faivre, S., Herzig, M. C., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., and Juniewicz, P. E. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol., 58: 920-927, 2000.
34. Raymond, E., Faivre, S., Woynarowski, J. M., and Chaney, S. G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol., 25: 4-12, 1998.
35. De Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., Papamichael, D., Le Bail, N., Louvet, C., Hendler, D., de Braud, F., Wilson, C., Morvan, F., and Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 18: 2938-2947, 2000.
36. Daud, A., Munster, P., Munster, P., and Spriggs, D. R. New drugs in gynecologic cancer. Curr. Treat Options Oncol., 2: 119-128, 2001.
37. ChauI, Webb, A., Cunningham, D., Hill, M., Rao, S., Ageli, S., Norman, A.; Gill, K., Howard, A., and Catovsky, D. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br. J. Haematol., 4: 786-792, 2001.
38. Graham, M. A., Lockwood, G. F., Greenslade, D., Brienza, S., Bayssas, M., and Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res., 6: 1205-1218, 2000.
39. Benjamin, R. S., Riggs, C. E., and Bachur, N. R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res., 37: 1416-1420, 1977.
40. Hande, K., Messenger, M., Wagner, J., Krozely, M., and Kaul, S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin. Cancer Res., 5: 2742-2747, 1999.
41. L-overexpressing chemotherapy-resistant tumor cells. Cancer Res., 60: 3051-3057, 2000.
42. Keogh, S. A., Walczak, H., Bouchier-Hayes, L., and Martin, S. J. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett., 471: 93-98, 2000.
43. Kim, E. J., Suliman, A., Lam, A., and Srivastava, R. K. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand. Int. J. Oncol., 18: 187-194, 2001.
44. Fulda, S., Meyer, E., and Debatin, K. M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 21: 2283-2294, 2002.
45. Munshi, A., Pappas, G., Honda, T., McDonnell, T. J., Younes, A., Li, Y., and Meyn, R. E. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene, 20: 3757-3765, 2001.
46. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., and Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res., 59: 734-741, 1999.
47. Vignati, S., Codegoni, A., Polato, F., and Broggini, M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur. J. Cancer, 38: 177-183, 2002.
48. Wu, X. X., Kakehi, Y., Mizutani, Y., Kamoto, T., Kinoshita, H., Isogawa, Y., Terachi, T., and Ogawa, O. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int. J. Oncol., 20: 949-954, 2002.
49. Odoux, C., Albers, A., Amoscato, A. A., Lotze, M. T., and Wong, M. K. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int. J. Cancer, 97: 458-465, 2002.
50. Munshi, A., McDonnell, T. J., and Meyn, R. E. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol., 50: 46-52, 2002.
51. Cuello, M., Ettenberg, S. A., Nau, M. M., and Lipkowitz, S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol., 81: 380-390, 2001.
52. Shin, E. C., Seong, Y. R., Kim, C. H., Kim, H., Ahn, Y. S., Kim, K., Kim, S. J., Hong, S. S., and Park, J. H. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp. Mol. Med., 34: 114-122, 2002.
53. Wu, G. S., Kim, K., and el-Deiry, W. S. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv. Exp. Med. Biol., 465: 143-151, 2000.
54. LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., and Ashkenazi, A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med., 8: 274-281, 2002.
55. Roth, W., and Reed, J. C. Apoptosis and cancer: when BAX is TRAILing away. Nat. Med., 8: 216-218, 2002.
56. Robertson, J. D., Enoksson, M., Suomela, M., Zhivotovsky, B., and Orrenius, S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J. Biol. Chem., 277: 29803-29809, 2002.
57. Lassus, P., Opitz-Araya, X., and Lazebnik, Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science (Wash. DC), 297: 1352-1354, 2002.